US · Healthcare · Biotechnology
EPS came in at -0.38 against a street estimate of -0.41 — a beat of 7.3%.
Analysts rate Enliven Therapeutics Inc. a strong buy (8 buy, 0 hold, 0 sell out of 8) with an average price target of $66.89.
| Fund | Stake |
|---|---|
| Orbimed Advisors, LLC | 11.14% |
| FMR Inc | 9.56% |
| Polar Capital Holdings PLC | 7.09% |
| BlackRock Inc | 5.16% |
| COMMODORE CAPITAL LP | 4.58% |
| Vestal Point Capital LP | 4.55% |
| Bellevue Group AG | 3.25% |
| Vanguard Capital Management, LLC | 3.04% |
| Document | Date |
|---|---|
| Material agreement · Q2 2026 | 2026-06-12 |
| Reg FD disclosure · Q2 2026 | 2026-06-11 |
| Charter / bylaws change · Q2 2026 | 2026-06-10 |
| Quarterly report · Q1 2026 | 2026-05-07 |
| Results announced · Q2 2026 | 2026-05-07 |
| Proxy statement · Q2 2026 | 2026-04-27 |
| Annual report FY2025 | 2026-03-03 |
| Quarterly report · Q3 2025 | 2025-11-12 |
Readable in the app.
Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Enliven Therapeutics Inc. — free to start.
Google PlayApp StoreData updated 2026-08-05.